TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies

Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an essential role in tumor initiation and progression. Therefore, immunotherapy, including immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) and chimeric antigen receptor T cell (CAR-T) t...

Full description

Bibliographic Details
Main Authors: Shenhe Jin, Ye Zhang, Fengping Zhou, Xiaochang Chen, Jianpeng Sheng, Jin Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
TIGIT
immunotherapy
hematological malignancy
lymphoma
multiple myeloma
leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1091782/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1091782/full

Similar Items